Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma

PURPOSE: Gemcitabine plus cisplatin is active in malignant mesothelioma (MM), although single-arm phase II trials have reported variable outcomes. Vascular endothelial growth factor (VEGF) inhibitors have activity against MM in preclinical models. We added the anti-VEGF antibody bevacizumab to gemci...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Kindler, Hedy L., Karrison, Theodore G., Gandara, David R., Lu, Charles, Krug, Lee M., Stevenson, James P., Jänne, Pasi A., Quinn, David I., Koczywas, Marianna N., Brahmer, Julie R., Albain, Kathy S., Taber, David A., Armato, Samuel G., Vogelzang, Nicholas J., Chen, Helen X., Stadler, Walter M., Vokes, Everett E.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2012
Teme:
Original Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3397785/
https://ncbi.nlm.nih.gov/pubmed/22665541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.41.5869
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki